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2ABSTRACT
Determining how transcriptional regulatory signals are encoded in vertebrate genomes is
essential for understanding the origins of multi-cellular complexity; yet the genetic code of
vertebrate gene regulation remains poorly understood.  In an attempt to elucidate this code,
we synergistically combined genome-wide gene expression profiling, vertebrate genome
comparisons, and transcription factor binding site analysis to define sequence signatures
characteristic of candidate tissue-specific enhancers in the human genome.  We applied
this strategy to microarray-based gene expression profiles from 79 human tissues and
identified 7,187 candidate enhancers that defined their flanking gene expression, the
majority of which were located outside of known promoters.  We cross-validated this
method for its ability to de novo predict tissue-specific gene expression and confirmed its
reliability in 57 of the 79 available human tissues, with an average precision in enhancer
recognition ranging from 32% to 63%, and a sensitivity of 47%.  We used the sequence
signatures identified by this approach to assign tissue-specific predictions to ~328,000
human-mouse conserved noncoding elements in the human genome.  By overlapping these
genome-wide predictions with a large in vivo dataset of enhancers validated in transgenic
mice, we confirmed our results with a 28% sensitivity and 50% precision.  These results
indicate the power of combining complementary genomic datasets as an initial
computational foray into the global view of tissue-specific gene regulation in vertebrates.
3INTRODUCTION
Increasing lines of evidence support the notion that the majority of functional elements in
the human genome do not code for proteins 1, 2, yet our ability to systematically categorize
and predict their function remains limited.  For instance, most progress in elucidating
transcriptional regulatory mechanisms has stemmed from computational and experimental
analyses of transcription factors (TFs) acting within promoter regions of functionally
related cohorts of genes.  While informative 3-6, these studies did not assess distant-acting
regulatory elements and thereby only sampled a limited portion of the vertebrate gene
regulatory network 7, 8.  Several recent studies have provided conclusive evidence that the
complex transcriptional expression pattern of human genes is mediated through multiple
discrete sequences, often located hundreds of kilobases (kb) away from their core
promoters 9, 10.  In these studies, evolutionary sequence conservation has served as a
reliable indicator of biological activity, with an increasing number of distant noncoding
evolutionary conserved regions (ECRs) validated as tissue-specific enhancers during
development 9-15.  Although genome comparisons have provided a powerful approach for
identifying noncoding ECRs that are under selective pressure, we have yet to develop
reliable high-throughput computational methods for the discovery of distant regulatory
elements with predetermined functional specificity.  Here we describe a strategy for
translating noncoding sequence data into transcriptional regulatory information that serves
two vital purposes: to define the genetic vocabulary of tissue-specific gene regulation and
to use this information to predict tissue-specific enhancers in the entire human genome, de
novo.  This approach combines genome-wide tissue-specific gene expression profiling
data 16, vertebrate genome comparisons, and pattern analysis of transcription factor
binding sites (TFBS), thus providing an initial foundation for deciphering vertebrate gene
regulation from a purely computational strategy.
4RESULTS
Predicting candidate regulatory elements for tissue-specific
genes
As a first step towards directly relating gene expression to comparative sequence data, we
clustered overlapping gene transcripts in the human genome and identified 18,504 unique
protein-coding loci (the boundaries of each locus were defined by the neighbouring genes,
independent of the absolute size of the locus; see Materials and Methods).  We next
assigned transcriptional information obtained from the GNF Atlas2 gene expression
database (gnfAtlas2) 16 to these genomic loci.  This included 79 human tissues with the
majority of human loci (85%) successfully linked to their corresponding gene expression
pattern.  For each represented tissue, we defined two sets of genes: high expressors and
low expressors.  The high expressor group included the top 300 most highly expressed
genes, while the low expressors included the bottom 5,000 least expressed genes.  Our
goal was to compare the genomic loci containing these two contrasting gene sets (across
available tissues) to search for possible shared DNA sequence features in the vicinity of
genes highly expressed in a given tissue.
We initially observed a strong correlation between the tissue specificity of a gene and the
size of the locus, such that loci of highly expressed genes in the central nervous system
(CNS) were on average significantly larger than the global median locus length.  In
contrast, loci corresponding to highly expressed genes in the immune system or various
tumour tissues were significantly shorter (Figure 1; Figure S1).  For example, the median
locus length of a human gene highly expressed in fetal brain was 245kb, while genes
5highly expressed in testis were on average 3.6 times shorter (68kb) (Figure S1).  We also
found that 10% of the brain and CNS loci coincided with vast noncoding regions termed
gene deserts 9 in the human genome (a 2-fold increase over the expected value; p-value <
1e-7), consistent with the observation that most enhancers identified within gene deserts,
to date, are biased towards brain and/or CNS expression during vertebrate development 9,
11, 17.  Finally, we observed a linear correlation between locus length and the number of
human/mouse noncoding ECRs regardless of the tissue under investigation (Figure S1E).
Recent studies suggest that the most highly conserved noncoding ECRs within a locus
commonly possess gene regulatory function 9, 18, 19.  Therefore, we selected the three most
conserved human/mouse noncoding ECRs for each of the 18,504 human genes in our
study, as well as noncoding ECRs overlapping with the gene’s promoter region (defined as
the 1.5kb region upstream of the transcription start site).   These selection criteria
generated a dataset of 60 thousand (k) candidate regulatory elements in the human
genome, comprising ~1% of the entire genomic sequence (on average 4.2 candidate
regulatory elements per locus).  For comparison, functional noncoding elements have been
previously estimated to span ~2-3% of the human genome 20, while the dataset defined in
this study corresponds to the most highly conserved portion of this functional dataset.
Classification of these elements based on their genomic location annotated 32% of these
candidate regulatory elements as intergenic, 28% as promoter, 20% as intronic, 13% as
3’UTR, and 8% as 5’UTR.  Approximately 24k of these elements flanked 6,059 genes
with the highest gene expression in at least one of the 79 tissues and ~55k of these
elements flanked 15,632 genes with the lowest gene expression (serving as a negative
control dataset).
6To explore the sequence motifs of these noncoding ECRs linked to genes displaying high
versus low expression in the same tissue, we used a previously described motif
identification strategy 21 and identified 1.8 million (M) evolutionarily conserved putative
TFBS within this dataset (see Materials and Methods).  We found that several individual
motifs were significantly enriched in 43 human tissues (Table S1).  For example, we
observed a strong association among NRF1, OCT, MEF2 and CREB, transcription factors
known to play key roles in brain and neuronal development 22-26 in candidate regulatory
elements from loci highly expressed in human fetal brain (Table S1A).  However, as
described in further detail below, no single TF by itself was sufficient to predict where a
candidate enhancer will drive gene expression.
Determining sequence signatures of candidate tissue-specific
enhancers
Based on the presumed combinatorial nature of multiple TFs to mediate a given
enhancer’s activity, we employed an analysis strategy that simultaneously scored the
impact of multiple TFBS motifs in an attempt to classify noncoding ECR candidate
enhancers based on sequence signatures that define gene expression in a particular tissue.
This was accomplished by assigning a weight to each TF that quantifies its association
with a given tissue.  By summing these TFBS motif weights, we were thus able to
generate a regulatory potential tissue-specificity score for each of the 24k candidate
enhancers of highly expressed genes as well as 55k background elements of the low
expressed genes.  This scoring scheme provided the means to optimize TF weights in an
7effort to enrich for positively scoring candidate enhancers in tissue-specific loci of highly
expressed genes while simultaneously minimizing their presence in loci of genes with low
expression (independently performed for each tissue; see Materials and Methods).  We
named this approach Enhancer Identification (or EI) and its application allowed us to
select candidate tissue-specific enhancers from the pool of conserved noncoding elements
in loci of genes highly expressed in a given tissue (Figure 2).  We performed EI analysis
independently on both human and mouse gene expression data and while we primarily
utilized human statistics in our discussion, mouse data analysis is provided in the
Supplementary Materials (Figures S1 and S2; Tables S2 and S7).
The EI scoring optimization allowed us to maximize our resolving power to the point
where 60% (+/-5%) of genes highly expressed in a tissue group contain signatures that are
present in less than 15% of the low expressed genes, for any given tissue (Figure 3B).  For
example, EI identified at least one fetal lung candidate enhancer for 65% of genes with
high fetal lung expression, while no such candidates were identified in the non-intergenic
regions (promoter, UTR, or intronic) of greater than 86% of genes with low fetal lung
expression (intergenic regions were excluded from the negative control group to prevent
potential associations with neighboring genes’ regulation; see Materials and Methods).  Of
the original 24k candidate regulatory elements linked to genes highly expressed in one or
more of the 79 available tissues, EI optimization identified 7,187 candidate enhancers with
signatures that defined tissue-specific expression.  Through this consolidation of the
dataset, we found that 47% of human noncoding ECRs defined as candidate enhancers
were predictive of expression in more than one tissue, consistent with our finding that 66%
of the human genes in this study are highly expressed in multiple tissues.  Since these
8candidate enhancers were assigned to different tissues that are functionally related (for
example, CD4 and CD8 T-cells) (Table S6), it is possible that the transcriptional
regulation of genes expressed in similar tissues could be achieved through shared gene
regulatory mechanisms.  These findings are consistent with in vivo expression data derived
from enhancer scans in transgenic mice indicating that one-third of embryonic enhancers
active during a single time-point in development drive expression in more than one tissue
type 9, 11, 12, 27.  Finally, we also found that 20% of highly expressed genes within our
dataset harbor more than one distinct candidate enhancer predicted to be active in the same
tissue, supporting the hypothesis that certain genes contain multiple discrete regulatory
elements that overlap in their enhancer activity 11, 28.
Since the EI method is based on the weighting of multiple TFs for their association with
tissue-specific expression, we sought to further explore the nature of this combinatorial TF
scoring scheme.  We found that in no case was a single TF sufficient to predict tissue-
specific gene expression, supporting the notion that tissue-specific gene regulation is a
direct result of interplay among multiple TFs.  To quantify the impact of an individual i-th
TF on predicting gene expression in a particular tissue t, we calculated the TF importance
parameter ( tiI ) defined as the product of the TF occurrence (percentage of tissue-specific
candidate enhancers with a particular conserved TFBS) and its weight, in a tissue-specific
group of candidate enhancers (Table S2).  Since TF importance compounds the effects of
TF occurrence and weight, it presents an integrative measure of the TF’s role in generating
high positive scores of tissue-specific candidate regulatory elements.  At the same time, it
minimizes the impact of TFs that are rare or have small weights and thus do not contribute
significantly to establishing either a positive or a negative tissue-specificity score.  This
9quantification allowed for the identification of cohorts of TFs in candidate enhancers
potentially involved in tissue-specific regulatory networks, i.e. those TFs both with high
weights and high occurrences.  As an example of a high TF impact on tissue-specific
regulation, the photoreceptor-specific CRX TF has the highest importance parameter value
in eye development (Table S2) consistent with the known function of this regulatory
protein in Cone-Rod Dystrophy (CRD), an inherited progressive disease that causes
deterioration of the cone and rod photoreceptor cells and leads to blindness 29.
To illustrate this method’s ability to predict functional enhancers, we examined two well
characterized enhancers, one for skeletal muscle and one for liver, flanking the human
cardiac/slow skeletal muscle troponin C (TNNC1) and the apolipoprotein B (APOB) genes,
respectively (Figure 4).  An EI scan of the TNNC1 locus first identified 4 noncoding ECRs
(out of 12 total) as candidate regulatory elements (two intergenic, one intronic, and one
promoter element).  Subsequent EI optimization then correctly predicted the noncoding
ECR in intron 1 as a skeletal muscle enhancer in precise agreement with the previously
defined TNNC1 skeletal muscle enhancer 30, 31.  In a second example, EI correctly
identified the APOB promoter element as a fetal liver (and adult liver) enhancer and
predicted transcription factors HNF4 and C/EBP to be activating APOB expression, in
concordance with previous experimental studies 32.
To explore the possibility of synergistic TF linkage that may be biologically required for
directing tissue-specific gene expression, we extracted the top 10 scoring TFs for each
tissue based on their importance in predicting tissue-specific expression.  As an example,
we focused on the TF characteristics of two similar tissue types: heart and skeletal muscle
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(Figure 5A) (a complete list of the top TF for each tissue is provided in Table S2).  We
observed that 5 of the top 10 TF predictions for both these muscle types are shared, four of
which (MEF2, SRF, Myogenin, and ERR1) are strongly linked to transcriptional
regulation in muscle tissue and associated to various human cardiac myopathies 33-36.  As a
second example, the top 10 TFs predictors of liver expression included Hepatocyte
Nuclear Factor 1 (HNF1), HNF4, PPAR, SREBP1, HNF4-DR1, NR2F2, and FRX-IR1
(Figure 5A), all of which are known regulatory proteins important in liver function 37-39.
These two examples highlight the biological plausibility of the EI’s method of tissue-
specific gene expression prediction.
To globally address the power of the predicted TF-tissue associations in addition to the
support gained from the above selected examples, we mapped TFs to the human genome
and determined the tissue gnfAtlas2 expression profile for each TF gene.  Our rationale
was that if tissue-specific gene expression predictiveness is based on TFBS density in
candidate enhancer sequences, then the TF required for this function should be expressed
in the tissue of activity.  Thus, we attempted to correlate positive TF importance with the
level of TF gene expression in the available 79 human tissues.  This was accomplished by
adjusting the minimal TF importance threshold increasingly from -0.25 to +0.25 (thus
gradually increasing the ratio of TFs with positive importance values in the group) to
determine if TF expression and enhancer predictiveness were positively correlated (Figure
5B).  Indeed, we observed that ~60% of predicted positive TF-tissue associations
corresponding to TF importance thresholds of ≥0.1 were supported by an increased level
of gene expression in the associated tissue (Figure 5B).  One possible explanation for the
lack of total concordance between the predicted TF-tissue associations and tissue-
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specificity is the ubiquitous nature of TF gene expression that often leads to ambiguous
definitions of tissue-specificity with increased and decreased level of gene expression in
gnfAtlas2.  Manual curation of these interactions, revealed that 90% (142/158) of
predicted TF-tissue associations with ≥0.25 TF importance threshold are supported by
published literature or alternative sources of experimental evidence (see Supplementary
Materials; Table S3).
Since any parametric optimization approach could potentially introduce “over-fitting” -
the identification of random profiles that separate genes with high versus low expression
purely by chance - we attempted to cross-validate our results.  This was accomplished by
characterizing the ability of the EI method to annotate tissue-specific enhancers in loci of
highly expressed genes without any a priori knowledge of tissue-specificity of gene
expression (i.e. these genes were excluded from the training set; see Materials and
Methods).  This approach allowed us to quantify both the method's precision (defined as
the proportion of predicted elements that act as tissue-specific enhancers) and sensitivity
for each tissue (Figure 3).  Through this analysis, we observed a high variability in EI
precision across the 79 sampled human tissues, and hence were classified into three
quality groups (Figure 3A): (1) poor (lower-bound precision, ↓P , less than 20%), (2)
good (lower-bound precision, ↓P  between 20-40%), and (3) excellent (lower-bound
precision, ↓P  greater than 40%) (Table 1).  Next, we grouped lower- and upper-bound
precision values to use their average as an estimate for the true precision and found that
72% (57/79) of human tissues have an average precision of 40%.  These data allowed us to
conclude that over-fitting did not account for the majority of signals obtained from the EI
predictive method.  In contrast, EI was suboptimal for the remaining 22 human tissues
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which fell into the poor category where the average precision was below 30%, indicating
that over-fitting likely explained a significant fraction of the signature derived for these
tissues.  Tissues comprised within this category mainly consisted of multiple gland and
germ tissues as well as structures such as the appendix and olfactory bulb.  Based on these
observations, we placed low significance values on the predictions derived for these
tissues and their enhancer predictions should be treated cautiously as they are likely to
represent false-positives.  In contrast, the average precision of the excellent group was
above 50% for 12 tissues including heart, liver, tongue, blood and several immune tissues
(Table 1).  Thus, these tissue-types bear the highest confidence of EI predictions.
Assigning tissue-specific predictions to conserved noncoding
sequences in the human genome
Since the EI method can generate tissue-specific predictions for any conserved element,
we used this approach to score 364k previously reported candidate enhancers in the human
genome 19 (see Materials and Methods).  In total, EI was able to assign a tissue-specificity
to 90% (328k) of these elements covering 4.0% of the human genome.  This large dataset
comprises tissue-specificity predictions for the majority (86%) of genes in the human
genome and represents a useful resource for detailed experimental follow-up studies by
gene-centric investigators.  We anticipated this latter approach to feature a relatively high-
rate of false-positive predictions since tissue-specificity of the predictions could not
always be supported by high expression of flanking genes.  However, this genome dataset
could represent an important resource for prioritizing tissue-specific enhancers in loci of
genes with known functions when one is interested in sifting through multiple
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evolutionary conserved elements and prioritizing only those that correspond to candidate
enhancers with matching tissue-specificity.  We should note that we observed an overlap
in tissue-specificity predictions as a result of several related tissues having similar EI
recognition profiles (Tables S6 and S7).  For example, 24% of CD4+ T-cell predicted
elements were also classified as CD8+ T-cell, while 14% of liver predicted elements were
simultaneously classified as fetal liver.  In contrast, only 0.8% of CD4+ T-cell predicted
elements were simultaneously classified as fetal liver predictions.  This suggests that the
direct EI tissue-specificity annotation of conserved elements may fail to distinguish
between closely related tissues, but can possibly distinguish between major tissue
categories or different organs.
Experimental validation of tissue-specific enhancer predictions
Based on our genome-wide predictions of tissue-specific activities for all noncoding
ECRs, we sought to determine their performance against existing enhancer data of gene
expression derived from transgenic mouse studies.  As a test bed, we examined the EI
tissue-specific predictions for 5 previously characterized enhancers expressed in the brain
and nervous system in the 1Mb region upstream of the DACH1 gene 9.  We found that 3 of
these elements were predicted to have enhancer activity limited to brain tissues while the 2
remaining elements were not assigned to any tissue (Table S4).  While these initial
correlations were based on a small sample set, the statistical significance of this match is
supported by a p-value of 0.004 (see Supplementary Materials).
To expand these data beyond the limited published in vivo data for distant-acting enhancer
elements, we next performed a large-scale analysis of our whole genome predictions
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against a publicly available dataset of 106 elements that have been shown to act as tissue-
specific enhancers in the mouse at embryonic day 11.5 of development (E11.5) (data
available at http://enhancer.lbl.gov) 27 (Table S5).  In this dataset we found 71 (67%)
enhancers to dictate expression in forebrain, midbrain, hindbrain, and/or neural tube.  We
thus assessed whether whole genome EI tissue-specific predictions overlap with these in
vivo characterized enhancers.  Indeed, 28% (20/71) of these elements were selectively
predicted as enhancers active in the brain and/or the nervous system.  In addition, another
7% (5/71) of these validated CNS-specific enhancers had EI predictions with a mixed
annotation of brain/CNS and another organ/tissue, suggesting these elements are possibly
multi-functional.  We also observed 21% (15/71) of predictions provided tissue
annotations inconsistent with the experimental data, while the remaining 44% (31/71)
elements had no tissue-specific prediction(s) (Table S5).  This corresponded to 28%
sensitivity and 50% precision in recognition of brain and CNS-specific enhancers using
the EI method, de novo.  By calculating the distribution of brain/CNS predictions in a
large random dataset (see Supplementary Materials) we found the overlap of this analysis
to be 2.5-fold greater than what would be expected by chance, corresponding to a p-value
of 0.0001.
To further explore the relationship between the 20 concordant EI whole genome
predictions and the existing in vivo nervous system dataset described above, we examined
the distribution of the predictions within the 18 different brain tissues present in gnfAtlas2
database.  While we found 4 or less of these in vivo defined CNS-enhancers were
predicted to be expressed in each of the 17 adult brain tissues present in the expression
annotation, 11 of them were annotated solely to the fetal brain category in the gnfAtlas2
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[the probability of this observation being random is less than 1e-7 (see Supplementary
Materials)].  This high ratio of fetal brain predictions is consistent with the entire in vivo
expression dataset that corresponds to a single time point of enhancer analysis during
embryonic development at E11.5.  This suggests that the fetal brain enhancer recognition
profile of EI is a specific signature of in vivo embryonic brain enhancers, in contrast to
enhancers active in specialized compartments of the adult brain.  Additional in vivo
datasets based on non-embryonic time points will further aid in assessing the ability of this
approach to predict enhancer elements active in adult tissues.
DISCUSSION
Deciphering the genetic code of gene regulation in vertebrate genomes remains a
significant challenge that has been partially aided by the availability of the human and
other vertebrate genome sequences.  However, while techniques such as comparative
genomics can enrich for putative enhancer sequences based on evolutionary conservation,
predicting their tissue-specificity has been difficult.  Nevertheless, several proof of
principle studies have demonstrated that there is a vaguely defined but computationally
recognizable genetic code of gene regulatory elements corresponding to selected
biological functions 40-42.  Additional studies have also revealed the power of microarray
expression data to correlate the distribution of evolutionary conserved putative TFBS in
the promoters of co-expressed human (and mouse) genes with the level and dynamics of
gene expression 43, 44.  These early focused studies suggest that computationally predicting
enhancer function is a solvable problem.  We therefore developed a multi-faceted
approach coupling TF binding specificities, comparative genomics, and microarray
expression data in an attempt to recognize sequence signatures within putative enhancer
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elements in the human genome.  Through these efforts, we show that it is possible to
identify tissue-specific enhancers for 72% of human sampled tissues by constructing
sequence recognition profiles based on the distribution of TFBS in noncoding ECRs
linked to genes expressed in similar tissues.
One of the inferences we can formulate based on the results of the EI method introduced
here is the proportion of enhancer activity assigned to promoters versus more distant-
acting sequences.  This measurement was possible since the EI approach utilizes the 3
most highly conserved human-mouse elements neighboring the gene under investigation
and thus goes beyond promoter only exploration of cis-regulatory features; the dominant
method currently employed in regulatory genomics.  Through the comparison of the EI
signal strength in promoter versus non-promoter conserved elements, we found that only
23% of EI candidate enhancers map to promoter regions of corresponding genes.  While a
caveat to this analysis is the incomplete status of precisely defined promoter boundaries,
this result is consistent with ChIP-chip and in vivo enhancer studies which also suggest
that more than half of human genes potentially rely on distant mechanisms of gene
regulation 7-10.
Since this method can be applied to the analysis of any set of co-expressed genes, this
provides a rapid and efficient approach for translating gene expression data into function-
specific gene regulatory principles.  Thereby, it should be straightforward to extend this
method to other tissues, developmental time-points, or functional gene categories (such as
Gene Ontology and KEGG datasets 45, 46, for example).  In addition, the elements
identified in this study represent a dataset of tissue-specific candidate enhancers that could
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be used to guide the ongoing large-scale experimental efforts aimed at exploring
transcriptional regulatory function in human, mouse and other vertebrate genomes.  Since
the backbone of the EI optimization method is the association of TFs with tissue-
specificities, we were able to predict over 7k such associations and retrieve experimental
evidence for 90% of them in a selected group of 158 TF-tissue associations (at a TF
importance threshold of 0.25).  Furthermore, characterization of TF spacing in predicted
tissue-specific enhancers allowed us to extract approximately one thousand TF pairs
significantly enriched as putative synergistic activators in a given tissue (see
Supplementary Materials).  While we were able to bring forth published evidence for
several predicted TF co-occurrences, the vast majority of TF-tissue linkages and their
potential interactions represent novel regulatory associations that could be used in
facilitating future studies of the complexities of gene regulatory pathways.
It is likely that general approaches that assign tissue-specificity to enhancer function will
greatly improve over time.  Current challenges include the varying quality of the human
and mouse microarray expression data and their primary adult material source that serves
to define gene expression tissue-specificities, the lack of in vivo spatial and temporal
enhancer data to further serve as training sets, and our incomplete knowledge of TFs as
well as their precise sequence-based binding properties currently available in the
TRANSFAC database 47.  In addition, the comparative analysis exploited here was limited
to human-mouse genome alignments under one alignment and conservation scoring
method.  Nevertheless, despite these limitations, our finding of EI’s ability to identify
tissue-specific enhancers with the available datasets is encouraging, and represents a
platform for further efforts in this area.
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In summary, the data presented here lend further support to the notion that sequence-based
features in vertebrate cis-regulatory elements are computationally recognizable, similar to
previous successes in the inference of coding, intron-exon, core promoter, and repetitive
DNA sequence signatures.  Even though our study is limited by the availability and
reliability of position weight matrices (PWM) of known TFs, the methods introduced here
present a universal framework for the de novo prediction of regulatory elements with
shared biological function, as well as for defining novel interactions among transcription
factors that can explain tissue-specific function of enhancer elements.  Future
computational efforts linked to topics such as human disease and vertebrate phenotypic
diversity are likely to provide insights into gene regulatory mechanisms of unexplained
biological phenomena.
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MATERIALS AND METHODS
Gene annotation and expression data. The UCSC Genome Browser 48 database was
used to extract gene positional information.  Human and mouse “knownGene”
transcripts49 were mapped to the NCBI Build 35 of the human (hg17) and mouse (mm7)
genomes and grouped into 18,504 and 17,636 non-overlapping loci, respectively.  GNF
Novartis Atlas2 tissue-specific gene expression 16 was extracted from the gnfAtlas2 table
and mapped to genes using the knownToGnfAtlas2 table (both tables are available in the
UCSC Genome Browser database).  At least one tissue-expression profile was available
for each of the 15,690 human and 14,303 mouse genes.
Profiling putative TFBS in the human genome. Human-mouse ECR Brower genome
alignments 50 were processed by rVista 2.0 21 to identify evolutionary conserved putative
TFBS in the human and mouse genomes.  We utilized previously described optimized
PWM thresholds 51, 52 to limit the appearance of predictions to 5 TFBS per 10kb of random
sequence.  In total, 13.4M conserved putative TFBS were identified using 554
TRANSFAC 9.4 PWMs 47 and 3 manually-curated PWMs for TBX5, NKX2.5, and GLI
TFs.  These putative TFBS were then grouped into 364 separate TF families (as several
TFs have multiple overlapping definitions in the TRANSFAC database) – we refer to
those TF families simply as TFs in the text – and superimposed with the 60k candidate
enhancers to construct a dataset of 1.8M putative TFBS in candidate enhancers for the
study.
Tissue-specific enrichment of individual putative TFBS. We calculated the ratio of
highly-to-lowly expressed gene loci containing putative TFBS in candidate enhancers for
different TFs and utilized the hypergeometric distribution with Bonferroni correction for
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multiple testing to identify significantly enriched putative TFBS in different tissues (Table
S1).
Assigning tissue specificity scores to candidate enhancers. We utilized the distribution
of putative TFBS inside a candidate enhancer (or noncoding ECR) to assign a tissue-
specificity score to that element.  First, we assigned a tissue specificity weight tiw  to each
i-th TF as a measure of its association with the tissue t.  Next, the distribution of putative
TFBS in the k-th candidate enhancer was scored to define candidate enhancer tissue-
specificity:
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where ikN  is the number of i-th TF putative TFBS located in the k-th candidate enhancer
and the summation is performed over all TFn  TFs.  TF weights were allowed to vary from
-1 to 10.  Large positive weights tiw  indicate a strong correlation between the i-th TF and
the t-th tissue-specificity, while large negative weights indicate the unlikely presence of
the i-th TF in a candidate enhancer that is active in the tissue t.
EI optimization to define TF tissue specificity weights.  To identify tissue-specific
candidate enhancers, we performed the Brent’s method optimization of TF weights tiw
that maximizes the number of positively scoring candidate enhancers in loci of highly
expressed genes ( +L ) and simultaneously minimizes the number of positively scoring
candidate enhancers in loci of lowly expressed genes ( −L ).  Optimization was performed
independently for different tissues.  To ensure a reliable and specific identification of
noncoding features in loci of highly expressed tissue-specific genes we included a large
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background dataset comprising 5,000 loci of lowly expressed genes assigned to each
tissue.  A scoring function tF ,
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containing summations over all positively scoring candidate enhancer associated with +L
( +⊂ Lk ) and −L  ( −⊂ Ll ) was maximized to perform the optimization of weights (the
distribution of positively scoring candidate enhancers in +L  and −L  was free to change
following the change in TF weights).  The ratio of the total number of candidate enhancers
in +L  ( +EN ) to the total number of candidate enhancers in −L  ( −EN ) was introduced
to the scoring function to account for differences in the number of highly and lowly
expressed genes and the number of corresponding candidate enhancers.  λ , or the signal
enrichment coefficient served to increase the negative impact of positively scoring
noncoding ECRs in −L .  λ  was selected as 1 during the initial optimization step and then
gradually increased to 10,000 to achieve the greatest separation between loci of highly and
lowly expressed genes.  Optimization was initialized with TF weights estimated using the
density of putative TFBS in +L  and −L  as
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Initial TF weights were upper-bounded by 1 and the optimization was performed
contiguously and recursively for each i-th TF.  It was interrupted after achieving an
increase less than 0.1 in the scoring function during a cycle of TF weights optimizations
across all TFs.  An important property of this optimization is the dynamic selection of the
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positively scoring subset of tissue-specific candidate enhancers from the original set of
candidate enhancers.
Cross-validation.
Cross-validations was performed by expanding the dataset of highly expressed genes to
400 and further subdividing this set into 2 groups consisting of 300 genes for EI
optimization and 100 genes for testing the signal recognition (test genes were not included
in the optimization).  Cross-validation was repeated four times to estimate the statistical
error in precision and sensitivity.  The four cross-validation replicas of 100 test genes did
not overlap with each other to ensure that four independent quantifications are carried out.
Similarly, each time a different group of 500 genes was removed from the background
dataset for each cycle of EI optimization.  Using this approach we performed four
independent rounds of EI optimization with 300 signal (highly expressed) and 4,500
background (lowly expressed) genes and subsequently applied the generated TF profiles to
independently calculate the percentage of tissue-specific candidate enhancers from the 100
test ( +R ) and 500 control ( −intR ) datasets.  Optimization and testing of control genes was
restricted to non-intergenic regions to avoid potential cross-talk with tissue-specific
enhancers controlling the expression of neighboring genes.  Therefore, EI precision in
recognizing tissue-specific enhancers (which measures the ratio of true positive tissue-
specific enhancers in the full  dataset  of predicted elements)
+
−+
↑ −=
R
RR
P int
represents the upper-bound estimate of the precision.  By excluding the non-intergenic
component of loci of test highly expressed genes from the quantification, after that, one
decreases the percentage of recognized test gense to +intR  and the corresponding precision
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−+
↓ −=
int
intint
R
RR
P
then represents the lower-bound of the precision of the method.  By averaging these two
values we were able to estimate the real precision of the method ( P ).  Also, +R  served as
an estimate for the lower-bound sensitivity of the method ( ↓Sn ) in the de novo
recognition of tissue-specific enhancers (which measures the probability of a tissue-
specific enhancer to be detected by EI) in cases where the corresponding gene does not
belong to a specific group of highly expressed genes.
Mapping TFs to known transcripts. We used information on TF gene names
corresponding to PWM used by the TRANSFAC database for automated (and manually-
curated after that) GenBank queries to identify the name and chromosomal location of the
human gene best matching each TF. For example, we were able to map the AML1 TF
matrix to the human runt-related transcription factor 1 (RUNX1) residing at chr21
(q22.12).  In total, 314 of 364 utilized TRANSFAC TFs were successfully mapped to
human genes.  In several instances, a TF mapped to more than one gene locus (in the case
of E2F1DP2 hetero-dimer, the TF complex mapped to E2F1 and TFDP2 genes; similarly
the SREBP TF mapped to both SREBP1 and SREBP2 genes); in such cases the expression
profiles were averaged across all genes corresponding to the TF or TF-complex.
Permutation analysis to identify significant tissue-specific inter-TF interactions. We
analyzed the distribution of positively scoring TFBS in tissue-specific candidate enhancers
independently of each tissue.  Only TFs with individual TF occurrence >= 5% or TF
importance >= 0.05 were sub-selected for the analysis.  The number of TF-TF pairs with
the minimal and maximal inter-TF distances of 5 and 100, respectively, was calculated for
each pair of TFs.  10,000 permutations randomizing the distribution of TF name labels
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among different TFBS were performed.  The total number of TFBS for each TF as well as
positions of individual TFBS was kept intact during the randomization.  We then extracted
a subset of TF pairs that occur less frequently in 95% of permutation tests than in the
original distribution (corresponding to a p-value < 0.05 to observe the original distribution
by chance) and that corresponded to at least a 2-fold increase in their density in the
original distribution as compared to an average pair density in permutation tests.
Assigning tissue-specific enhancer predictions to a whole genome dataset of human-
mouse noncoding ECRs. We profiled TFBS distributions for 364k previously catalogued
human/mouse conserved noncoding sequences 19, and a comprehensive 1.4M noncoding
ECRs set for the entire human genome, to identify 328k and 588k elements, respectively,
that have a positive tissue-specificity score according to EI tissue-specificity profiles.  We
used a p-value 0.05 cut-off for the 364K set that corresponds to an estimate of 0.05 false
positive enhancer predictions per 10kb of random sequence 19.  In cases of multiple tissue
associations assigned to an elements we selected up to three top scoring associations with
the score of at least 50% of the most top scoring tissue-association (data available at
http://www.dcode.org/EI).  The same score selection procedure was applied for the
analysis of organ specificities.
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FIGURE LEGENDS
Figure 1.  Locus length of human genes highly expressed in several tissues.  Bound
horizontal lines represent the inter-quartile range (the distance between the 25th and 75th
percentiles) of the tissue-specific distributions, solid colored rectangles measure the
standard error in median calculations (median locus length is depicted by a white line
inside colored rectangles.  Statistically significant (<5%) distributions that deviate from
the global median (represented by a solid vertical black line) are marked by an asterisk on
the left side bar.  Tissues with a median value two-fold smaller or larger than the median
are marked by a vertical line on the left side bar.
Figure 2. Schematic of the general EI strategy for defining signatures of tissue-specific
enhancers.
Figure 3. Precision (A) and sensitivity (B) of the EI method in recognizing human tissue-
specific enhancers.  Lower- and upper- bound estimates of precision along with their
average are given in red, blue, and black on precision plots (A), respectively.  Standard
deviation is also depicted for each lower and upper bound estimates.  Tissues are split into
poor, good, and excellent groups based on the lower-bound estimate of the precision.  See
Figure S2 for corresponding mouse data.  Navy and red curves on sensitivity plots (B)
measure the percentage of high and low expressed gene loci with tissue-specific
enhancers, respectively; while the purple curve estimates EI sensitivity for de novo
enhancer recognition.
Figure 4. EI annotation of TNNC1 skeletal muscle (A) and APOB (B) liver enhancer.
Zoomed-in view of Mulan 51 human/mouse evolutionary conservation profiles for these
loci depicts candidate enhancer elements followed by profile of conserved TFBS present
within.
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Figure 5. Importance and occurrence of individual TFs in candidate enhancers
corresponding to mouse liver, B-cells, heart, and skeletal muscle (A).  Binning of 25k
predicted TF-tissue associations by a minimal TF importance threshold (B).  The number
of TF-tissue associations almost does not change in the area of negative TF importance
thresholds and rapidly decreases in the area of positive TF importance thresholds (dark red
graph; right y-axis) indicative of a small number of TFs with large positive importance
values and an even smaller number of TFs with large negative importance values.  The
percentage of TF-tissue associations that are confirmed by an increase in TF gene
expression (orange bars) increases with the increase of minimal TF importance (followed
by the corresponding decrease in the number of non-confirmed associations – blue bars).
As ~60% of predicted TF-tissue associations with a minimal TF importance of 0.1 are
supported by an increased level of TF gene expression in the corresponding tissue this
threshold could serve as a cut-off of reliability in TF-tissue association predictions.
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Table 1. Separation of human tissues into three precision groups. Tissues in a group list
are sorted by the average EI precision so that tissues with the highest precision are listed
lastly.
Precision
group
Tissues
poor pituitary gland, thymus, testis Leydig cell, cardiac myocytes, adrenal gland, salivary gland, testis,
leukemia chronic myelogenous (k562), hypothalamus, testis germ cell, bronchial epithelial cells,
pancreatic islets, olfactory bulb, fetal thyroid, dorsal root ganglion, atrioventricular node, appendix,
testis interstitial, thyroid, ovary, skin, testis seminiferous tubule, skeletal muscle
good prostate, smooth muscle, thyroid, amygdala, medulla oblongata, cingulate cortex, uterus corpus,
prefrontal cortex, BM-CD71+ early erythroid, spinal cord, pancreas, BM-CD105+ endothelial, PB-
CD4+ Tcells, lymphoma Burkitts Daudi, adipocyte, ciliary ganglion, subthalamic nucleus, trigeminal
ganglion, adrenal cortex, whole brain, caudate nucleus, colorectal adenocarcinoma, leukemia
promyelocytic (hl60), pons, globus pallidus, cerebellum peduncles, fetal brain, temporal lobe, PB-
CD19+ Bcells, uterus, superior cervical ganglion, lymphoma Burkitts Raji, occipital lobe, PB-CD8+
Tcells, placenta, tonsil, thalamus, trachea, BM-CD34+, fetal liver, fetal lung, parietal lobe, kidney, PB-
BDCA4+ dentritic cells, PB-CD14+ monocytes
excellent PB-CD56+ NKCells, tongue, BM-CD33+ myeloid, cerebellum, bone marrow, lung, leukemia
lymphoblastic (molt4), 721 B lymphoblasts, heart, whole blood, lymph node, liver
34
References
1. Altshuler, D. et al. A haplotype map of the human genome. Nature 437, 1299-1320
(2005).
2. Lindblad-Toh, K. et al. Genome sequence, comparative analysis and haplotype
structure of the domestic dog. Nature (2005).
3. Sharan, R., Ben-Hur, A., Loots, G.G. & Ovcharenko, I. CREME: Cis-Regulatory
Module Explorer for the human genome. Nucleic Acids Res 32, W253-256 (2004).
4. Kim, T.H. et al. A high-resolution map of active promoters in the human genome.
Nature 436, 876-880 (2005).
5. Bajic, V.B., Tan, S.L., Suzuki, Y. & Sugano, S. Promoter prediction analysis on
the whole human genome. Nat Biotechnol 22, 1467-1473 (2004).
6. Xie, X. et al. Systematic discovery of regulatory motifs in human promoters and 3'
UTRs by comparison of several mammals. Nature 434, 338-345 (2005).
7. Cawley, S. et al. Unbiased mapping of transcription factor binding sites along
human chromosomes 21 and 22 points to widespread regulation of noncoding
RNAs. Cell 116, 499-509 (2004).
8. Levine, M. & Tjian, R. Transcription regulation and animal diversity. Nature 424,
147-151 (2003).
9. Nobrega, M.A., Ovcharenko, I., Afzal, V. & Rubin, E.M. Scanning human gene
deserts for long-range enhancers. Science 302, 413 (2003).
10. Lettice, L.A. et al. A long-range Shh enhancer regulates expression in the
developing limb and fin and is associated with preaxial polydactyly. Hum Mol
Genet 12, 1725-1735 (2003).
11. de la Calle-Mustienes, E. et al. A functional survey of the enhancer activity of
conserved non-coding sequences from vertebrate Iroquois cluster gene deserts.
Genome Res 15, 1061-1072 (2005).
12. Woolfe, A. et al. Highly conserved non-coding sequences are associated with
vertebrate development. PLoS Biol 3, e7 (2005).
13. Loots, G.G. et al. Identification of a coordinate regulator of interleukins 4, 13, and
5 by cross-species sequence comparisons. Science 288, 136-140 (2000).
14. Dermitzakis, E.T., Reymond, A. & Antonarakis, S.E. Conserved non-genic
sequences - an unexpected feature of mammalian genomes. Nat Rev Genet 6, 151-
157 (2005).
15. Emison, E.S. et al. A common sex-dependent mutation in a RET enhancer
underlies Hirschsprung disease risk. Nature 434, 857-863 (2005).
16. Su, A.I. et al. Large-scale analysis of the human and mouse transcriptomes. Proc
Natl Acad Sci U S A 99, 4465-4470 (2002).
17. Uchikawa, M., Takemoto, T., Kamachi, Y. & Kondoh, H. Efficient identification
of regulatory sequences in the chicken genome by a powerful combination of
embryo electroporation and genome comparison. Mech Dev 121, 1145-1158
(2004).
18. Ovcharenko, I., Stubbs, L. & Loots, G.G. Interpreting mammalian evolution using
Fugu genome comparisons. Genomics 84, 890-895 (2004).
19. Prabhakar, S. et al. Close sequence comparisons are sufficient to identify human
cis-regulatory elements. Genome Res (2006).
35
20. Waterston, R.H. et al. Initial sequencing and comparative analysis of the mouse
genome. Nature 420, 520-562 (2002).
21. Loots, G.G. & Ovcharenko, I. rVISTA 2.0: evolutionary analysis of transcription
factor binding sites. Nucleic Acids Res 32, W217-221 (2004).
22. Riccio, A. et al. A nitric oxide signaling pathway controls CREB-mediated gene
expression in neurons. Mol Cell 21, 283-294 (2006).
23. Shalizi, A.K. & Bonni, A. Brawn for Brains: The Role of MEF2 Proteins in the
Developing Nervous System. Curr Top Dev Biol 69, 239-266 (2005).
24. Chang, W.T., Chen, H.I., Chiou, R.J., Chen, C.Y. & Huang, A.M. A novel
function of transcription factor alpha-Pal/NRF-1: increasing neurite outgrowth.
Biochem Biophys Res Commun 334, 199-206 (2005).
25. Ilia, M., Sugiyama, Y. & Price, J. Gender and age related expression of Oct-6--a
POU III domain transcription factor, in the adult mouse brain. Neurosci Lett 344,
138-140 (2003).
26. Okuda, T. et al. Oct-3/4 repression accelerates differentiation of neural progenitor
cells in vitro and in vivo. Brain Res Mol Brain Res 132, 18-30 (2004).
27. Pennacchio, L.A. et al. Nature (submitted).
28. Frazer, K.A. et al. Noncoding sequences conserved in a limited number of
mammals in the SIM2 interval are frequently functional. Genome Res 14, 367-372
(2004).
29. Itabashi, T. et al. Novel 615delC mutation in the CRX gene in a Japanese family
with cone-rod dystrophy. Am J Ophthalmol 138, 876-877 (2004).
30. Christensen, T.H., Prentice, H., Gahlmann, R. & Kedes, L. Regulation of the
human cardiac/slow-twitch troponin C gene by multiple, cooperative, cell-type-
specific, and MyoD-responsive elements. Mol Cell Biol 13, 6752-6765 (1993).
31. Parmacek, M.S. et al. A novel myogenic regulatory circuit controls slow/cardiac
troponin C gene transcription in skeletal muscle. Mol Cell Biol 14, 1870-1885
(1994).
32. Novak, E.M., Dantas, K.C., Charbel, C.E. & Bydlowski, S.P. Association of
hepatic nuclear factor-4 in the apolipoprotein B promoter: a preliminary report.
Braz J Med Biol Res 31, 1405-1408 (1998).
33. Parlakian, A. et al. Temporally controlled onset of dilated cardiomyopathy through
disruption of the SRF gene in adult heart. Circulation 112, 2930-2939 (2005).
34. Sakuma, K. et al. Serum response factor plays an important role in the
mechanically overloaded plantaris muscle of rats. Histochem Cell Biol 119, 149-
160 (2003).
35. Kadi, F., Johansson, F., Johansson, R., Sjostrom, M. & Henriksson, J. Effects of
one bout of endurance exercise on the expression of myogenin in human
quadriceps muscle. Histochem Cell Biol 121, 329-334 (2004).
36. Huss, J.M., Torra, I.P., Staels, B., Giguere, V. & Kelly, D.P. Estrogen-related
receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in
the transcriptional control of energy metabolism in cardiac and skeletal muscle.
Mol Cell Biol 24, 9079-9091 (2004).
37. Shih, D.Q. et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile
acid and plasma cholesterol metabolism. Nat Genet 27, 375-382 (2001).
38. Zannis, V.I., Kan, H.Y., Kritis, A., Zanni, E. & Kardassis, D. Transcriptional
regulation of the human apolipoprotein genes. Front Biosci 6, D456-504 (2001).
36
39. Cheng, W. et al. HNF factors form a network to regulate liver-enriched genes in
zebrafish. Dev Biol (2006).
40. Hallikas, O. et al. Genome-wide prediction of mammalian enhancers based on
analysis of transcription-factor binding affinity. Cell 124, 47-59 (2006).
41. Sun, Q. et al. Defining the mammalian CArGome. Genome Res 16, 197-207
(2006).
42. Thompson, W., Palumbo, M.J., Wasserman, W.W., Liu, J.S. & Lawrence, C.E.
Decoding human regulatory circuits. Genome Res 14, 1967-1974 (2004).
43. Sharan, R., Ovcharenko, I., Ben-Hur, A. & Karp, R.M. CREME: a framework for
identifying cis-regulatory modules in human-mouse conserved segments.
Bioinformatics 19 Suppl 1, i283-291 (2003).
44. Das, D., Nahle, Z. & Zhang, M.Q. Adaptively inferring human transcriptional
subnetworks. Mol Syst Biol 2, 2006 0029 (2006).
45. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res 28, 27-30 (2000).
46. Harris, M.A. et al. The Gene Ontology (GO) database and informatics resource.
Nucleic Acids Res 32, D258-261 (2004).
47. Wingender, E. et al. TRANSFAC: an integrated system for gene expression
regulation. Nucleic Acids Res 28, 316-319 (2000).
48. Kent, W.J. et al. The human genome browser at UCSC. Genome Res 12, 996-1006
(2002).
49. Karolchik, D. et al. The UCSC Genome Browser Database. Nucleic Acids Res 31,
51-54 (2003).
50. Ovcharenko, I., Nobrega, M.A., Loots, G.G. & Stubbs, L. ECR Browser: a tool for
visualizing and accessing data from comparisons of multiple vertebrate genomes.
Nucleic Acids Res 32, W280-286 (2004).
51. Ovcharenko, I. et al. Mulan: multiple-sequence local alignment and visualization
for studying function and evolution. Genome Res 15, 184-194 (2005).
52. Cartharius, K. et al. MatInspector and beyond: promoter analysis based on
transcription factor binding sites. Bioinformatics 21, 2933-2942 (2005).
